Bioassociate Initiated Coverage On KaloBios Pharmaceuticals With A Buy
Aug. 10, 2015, 8:25 AM
- KaloBios Pharmaceuticals (NASDAQ:KBIO): Q2 EPS of -$1.46 beats by $0.22.
May 11, 2015, 8:12 AM
- KaloBios Pharmaceuticals (NASDAQ:KBIO): Q1 EPS of -$0.29 beats by $0.01.
Mar. 16, 2015, 3:23 PM
- KaloBios Pharmaceuticals (NASDAQ:KBIO): FY14 EPS of -$1.15
Nov. 6, 2014, 5:38 PM
- KaloBios Pharmaceuticals (NASDAQ:KBIO): Q3 EPS of -$0.24 beats by $0.10.
Aug. 7, 2014, 8:53 AM
- KaloBios Pharma (NASDAQ:KBIO): Q2 EPS of -$0.30 beats by $0.04.
Nov. 12, 2013, 8:57 AM
- KaloBios Pharmaceuticals (KBIO): Q3 EPS of -$0.47.
- Revenue of $9K. (PR)
Aug. 19, 2013, 12:47 PM
- KaloBios Pharmaceuticals (KBIO -2.3%) slips after its Q2 loss came in greater than Street expectations.
- The company attributes the loss to increased spending for clinical trial programs and higher SG&A expenses associated with being a public company.
- Contract revenues were $15K, down from the prior-year period's $2.99M.
May 15, 2013, 7:54 AMKaloBios Pharmaceuticals (KBIO): Q1 EPS of -$0.55 misses by $0.10. Revenue of $16K misses by $484K. | May 15, 2013, 7:54 AM
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.
Industry: Drug Manufacturers - Major
Country: United States
Other News & PR